Médecine

Paramédical

Autres domaines


S'abonner

A historical cohort study to investigation of statins safety in COVID-19 hospitalized patients - 12/11/21

Doi : 10.1016/j.therap.2021.10.006 
Saeed Nateghi a, Mohammad Mahmoudi Gomari b, Hadiseh Hosamirudsari c, Behnam Behnoush d, Asma Razmjoofard e, Goli Azimi a, Shokooh Ordookhani a, Ali Jafarpour f, g, Neda Faraji a,
a Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran 
b Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran 
c Department of Infectious Diseases, Baharloo Hospital, Railway Square, Tehran University of Medical Sciences, Tehran, Iran 
d Department of Forensic Medicine, Tehran University of Medical Sciences, Tehran, Iran 
e School of Medicine, Tehran University of Medical Sciences, Tehran, Iran 
f Gerash Amir-al-Momenin Medical and Educational center, Gerash University of Medical Science, Gerash, Iran 
g Research center for clinical virology, Tehran university of medical science, Tehran, Iran 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 12 November 2021

Summary

Background and objectives

A notable proportion of COVID-19 patients need statins for their co-existing conditions. Statins possess several anti-inflammatory properties. We have attempted to describe potential association of exposure to statins and severity of COVID symtpoms in a historical study in hospitalized COVID-19 patients.

Methods

This single-center, historical cohort study was performed in Baharloo hospital as a referral hospital for COVID-19 patients in Tehran. Patients were divided into two groups; 163 statins users and 547 non-users. Mortality rate, intensive care unit (ICU) admission and length of hospitalization were compared between studied groups. In addition, during the investigation, pre-existing conditions were evaluated for groups. If a significant difference was observed between groups, the feature was considered in the adjustment of the odds ratio.

Results

At the beginning, statistical analysis study showed that statins users had significantly (p<0.0001) higher mortality rate, ICU admission and length of hospitalization. But after implementation of variables such as age, sex, diabetes, hypertension status, stroke, dyslipidemia, cardiovascular diseases, chronic kidney disease (CKD), corticosteroids, renin-angiotensin-aldosterone axis inhibitors and proton pump inhibitors (PPIs) for adjustment of the odds ratio, a considerable alteration appeared in the studied values. Following adjustment of odds ratio it was shown that statins did not change mortality (95% CI, OR 0.71 (0.41–1.22), p=0.22), ICU admission (95% CI, OR 1.05 (0.66–1.66), p=0.835) and length of hospitalization (95% CI, OR 1.30 (0.78–2.17), p=0.311). In addition, we found that statins could not decrease inflammatory markers in COVID-19 infected patients.

Conclusion

The use of statins did not seem to change outcomes in COVID19.

Le texte complet de cet article est disponible en PDF.

Keywords : Statins, COVID-19, Statistics, SARS-CoV-2, Mortality, ICU admission


Plan


© 2021  Société française de pharmacologie et de thérapeutique. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.